Medical

A study published May 19, 2019 in the New England Journal of Medicine found that the Symbicort Turbuhaler budesonide/formoterol DPI demonstrated a greater than 50% reduction in the risk of asthma exacerbations in mild asthma patients compared to as-needed albuterol (salbutamol) alone. Compared to as-needed albuterol used in conjunction with maintenance budesonide, … [Read more...] about Study finds as-needed budesonide/formoterol superior to as-needed albuterol (salbutamol) for reducing risk of severe exacerbations in mild asthma

Respivant Sciences has announced dosing of the first patient in the Phase 2b SCENIC trial of its RVT-1601 cromolyn sodium inhalation solution for the treatment of cough in idiopathic pulmonary fibrosis (IPF) patients. Respivant was spun off from Roivant in September 2018 specifically to develop RVT-1601. Roivant acquired the cromolyn sodium inhalation solution, … [Read more...] about Respivant initiates Phase 2b study of RVT-1601 for IPF cough

Glenmark Pharmaceuticals recently said that a Phase 3 study comparing Ryaltris olopatadine hydrochloride to placebo in seasonal allergic rhinitis patients aged 6 up to 12 years achieved its primary endpoint. The 14-day study, which enrolled 446 patients, demonstrated a statistically significant improvement in average Reflective Total Nasal Symptom Score (rTNSS), with … [Read more...] about Phase 3 study of Ryaltris nasal spray for treatment of allergic rhinitis in pediatric patients met primary endpoint

Verona Pharma said that it has initiated a Phase 2b dose-ranging study of RPL554 nebulized ensifentrine for the treatment of COPD, with results expected by the end of 2019. The company, which reported positive results from a Phase 2 study of an ensifetrine DPI in March 2019, said that it also expects to start a Phase 2 trial of an ensifetrine MDI for COPD this quarter … [Read more...] about Verona initiates Phase 2b study of nebulized ensifentrine for COPD

GlaxoSmithKline and Innoviva have announced that the Phase 3 CAPTAIN (Clinical study of Asthma Patients receiving Triple therapy through A single INhaler) study comparing the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) DPI to the Relvar/Breo Ellipta FF/VI DPI in patients with uncontrolled asthma met its primary endpoint. The CAPTAIN … [Read more...] about Phase 3 study of Trelegy Ellipta for the treatment of asthma meets primary endpoint

Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, "The top line results are now available and show that Budesolv achieves at least the same effect as the product which is currently on the market, with a significantly lower dose." According to … [Read more...] about Marinomed Biotech says Phase 3 trial of Budesolv nasal spray met primary endpoint

Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a single 20 mg dose of OP0201 or placebo and were then exposed to pressure changes in a pressure chamber. In the other, adults with acute otitis media received 20 … [Read more...] about Phase 1 trials of intranasal MDI for otitis media meet primary endpoints